Weight loss
The revolutionary once-weekly GLP-1 medication that helps your body feel full faster and longer, leading to significant weight loss while also protecting your heart—FDA approved and backed by some of the largest clinical trials in obesity medicine history.
Start here
Semaglutide is a once-weekly medication that mimics GLP-1, a natural gut hormone that tells your brain you are full 313. In clinical trials it produced substantial weight loss, averaging 15% of body weight 1, and it reduced cardiovascular risk by 20% in people with obesity and heart disease 2. It also improves blood sugar control in type 2 diabetes 58. It is FDA approved for this use, backed by some of the largest clinical trials in obesity medicine, and is taken as a weekly injection or a daily oral tablet.
Imagine your gut has a 'fullness hormone' called GLP-1 that tells your brain when you've eaten enough. The problem is, this natural hormone only lasts a few minutes before breaking down. 3 Semaglutide is like a super-powered, long-lasting version of that hormone. It's been modified so it stays active in your body for a whole week instead of minutes. When you take it, your brain gets a continuous 'I'm satisfied' signal, making you naturally want to eat less. It also slows down how fast food leaves your stomach, so you feel full longer after smaller meals. 7 The result? You lose weight because you're genuinely less hungry—not because you're white-knuckling through deprivation.
Semaglutide is a GLP-1 receptor agonist (a drug that switches on the receptor for the gut hormone GLP-1 (a gut hormone that tells your brain you're full)). It is 94% homologous (matching in structure) to natural human GLP-1. Two key changes make it last. Swapping the amino acid at position 8 (Ala to Aib) makes it resist DPP-4, an enzyme that normally destroys GLP-1. And an 18-carbon fatty diacid chain attached through a spacer at Lys26 lets it bind to albumin (a blood protein) without a permanent chemical bond. 712 This gives a half-life (how long it stays active in your body) of approximately 168 hours (compared with 2-3 minutes for natural GLP-1), which allows one dose a week. 37 Semaglutide switches on GLP-1 receptors in several tissues. These are the beta cells of the pancreas (releasing insulin only when blood sugar is high), the alpha cells of the pancreas (lowering glucagon), the stomach lining (slowing stomach emptying), and neurons in the hypothalamus (cutting appetite by turning on POMC/CART neurons and turning off NPY/AgRP neurons, two groups of brain cells that lower or raise hunger). 13 Weight loss comes mainly from actions in the central nervous system that reduce hunger, increase fullness, and lower food reward (the pleasure drive to eat). The heart and blood vessel benefits seem to have several causes: direct effects on blood vessels, anti-inflammatory actions (lower hsCRP, a blood marker of inflammation), better blood fats (lipid profiles), and indirect effects from weight loss and better blood sugar 1222.
Evidence check
Well studied in people
This has been through large human trials — the strongest kind of evidence. Scientists have tested it on many people and measured what actually happened.
Every numbered marker on this page links to one of the 22 sources at the bottom.
Weight Loss
Produces 15%+ average body weight loss in clinical trials—among the most effective non-surgical weight loss interventions ever studied
Appetite Control
Dramatically reduces hunger and food cravings by mimicking natural satiety hormones, making portion control feel effortless rather than forced
Heart Protection
Proven 20% reduction in cardiovascular events (heart attacks, strokes, CV death) in the SELECT trial—a first for weight loss medications
The most-asked question
Semaglutide is dose-escalated: the studies start everyone low and step the dose up on a schedule, so the right amount depends on the week you're on. The research-reported maintenance range is 0.5–1 mg, once weekly.
4 weeks
0.25 mg
This is the starter dose to help your body adjust. It does not lower blood sugar much on its own, so it is only used for the first 4 weeks before stepping up 5.
At least 4 weeks at each step
0.5-1 mg
After the starter month, the dose goes up to 0.5 mg, and can rise to 1 mg if more blood sugar control is needed. Wait at least 4 weeks before each increase 5.
Ongoing
2-2.4 mg
The highest weekly doses. 2 mg is the maximum for diabetes (Ozempic) 5; up to 2.4 mg is used for weight management (Wegovy) after a slower titration (stepping the dose up gradually).
30 days
3 mg
The pill form (Rybelsus) starts at 3 mg each morning for 30 days. Like the starter shot, this dose is for getting started and does not control blood sugar by itself. Take on an empty stomach with a small sip of water, 30 minutes before food or other pills 6.
30+ days
7 mg
After the first 30 days, the dose increases to 7 mg once daily. This is the first dose that actively lowers blood sugar 6.
Ongoing
14 mg
The highest pill dose, used if more blood sugar control is needed after at least 30 days at 7 mg 6.
The ceiling: 2.4 mg once weekly for weight management; 7 2.0 mg for diabetes (Ozempic); 5 7.2mg dose under investigation 20
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Semaglutide:
Semaglutide comes in pre-filled, pre-measured pens. For Wegovy: Starter pens contain set doses (0.25mg, 0.5mg, etc.) that you select. For Ozempic: The pen dial lets you select your dose (0.25mg, 0.5mg, 1mg, or 2mg). No calculations needed—the pen does the measuring for you.
Simply dial your prescribed dose on the pen. For example, if prescribed 0.5mg weekly, turn the dose selector to 0.5mg and inject. The pen window shows your selected dose. One pen typically contains multiple doses depending on your prescription.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Semaglutide's recorded schedule.
Injection sites & technique
Injection under the skin (into the fatty tissue just under the skin)—quick, relatively painless, and can be self-administered at home
Timing
Choose any day of the week that works for your schedule and stick with it. Many people prefer Sunday or Monday to make it easy to remember. Take it at roughly the same time each week, though the exact hour doesn't matter much due to the long half-life (how long it stays active in your body) 57.
Semaglutide injections can be taken with or without food—it doesn't affect absorption. However, because the medication slows stomach emptying, eating smaller meals will help reduce nausea. The oral version (Rybelsus) MUST be taken on an empty stomach with a small amount of water.
Semaglutide is typically used as a standalone weight management therapy. If using with other diabetes medications, especially insulin or sulfonylureas, doses of those medications may need to be reduced to prevent low blood sugar. Always coordinate with your healthcare provider 57.
The honest list
These show up most often. They usually fade as your body adjusts.
The most frequently reported side effect, affecting about 44% of users at higher doses. 7 Usually worst during the first few weeks and when increasing doses, then typically improves significantly 1.
What to do Eat smaller meals, avoid fatty or fried foods, stay upright after eating, and consider ginger or peppermint tea. The slow dose escalation protocol specifically minimizes this. If severe, your doctor may slow the dose increases.
GI motility changes are common as semaglutide slows stomach emptying. Some people experience constipation, others diarrhea, and some alternate between both 7.
What to do Stay well hydrated, increase fiber intake gradually, and maintain physical activity. Over-the-counter remedies like stool softeners (for constipation) or anti-diarrheals can help. Symptoms usually improve over time.
This is actually how semaglutide works—it's a feature, not a bug. You'll naturally want to eat less and feel full faster. Some people find this dramatic enough that they forget to eat 37.
What to do While reduced appetite is the goal, make sure you're still eating regular nutritious meals. Focus on protein and vegetables at each meal. Skipping meals entirely can lead to muscle loss and nutritional deficiencies.
About 24% of users experience vomiting, especially during dose increases. 7 Like nausea, it's typically transient and improves as your body adjusts 1.
What to do Eat bland foods, avoid lying down after meals, and stay hydrated. If vomiting is frequent, contact your healthcare provider—they may recommend staying at the current dose longer before increasing.
Worth knowing about, but most people never see these.
Rapid weight loss (from any cause) increases gallstone risk. About 2-3% of users in trials developed gallbladder issues including gallstones, cholecystitis, or needed gallbladder removal 7.
What to do Report any severe upper abdominal pain, especially if it radiates to your back or right shoulder, or occurs after eating fatty foods. Some doctors recommend ursodiol for gallstone prevention during rapid weight loss.
Some users report temporary hair shedding, which is actually related to rapid weight loss rather than the medication itself. This can happen with any significant weight loss 717.
What to do Ensure adequate protein intake (at least 60-80g daily), consider biotin supplements, and know that this is usually temporary. Hair typically regrows once weight stabilizes.
Rare, but if any of these happen, stop and contact a medical professional.
Rare but serious inflammation of the pancreas. Risk is about 1 in 200 users. Symptoms include severe abdominal pain that radiates to the back, often with nausea and vomiting 716.
What to do STOP semaglutide immediately and seek emergency care if you experience severe abdominal pain. Do not restart semaglutide if you've had pancreatitis. People with history of pancreatitis should not use this medication.
Semaglutide caused thyroid C-cell tumors in rodents. It's unknown if this occurs in humans. After years of widespread use, no clear signal of increased thyroid cancer has emerged in people 715.
What to do Do not use if you or a family member has had medullary thyroid carcinoma (MTC) or MEN2 syndrome. Report any neck lump, persistent hoarseness, trouble swallowing, or shortness of breath to your doctor promptly.
Week by week
Is it right for you?
Semaglutide is a prescription medication that should only be started, adjusted, or stopped under medical supervision. This information is educational and does not replace professional medical advice. Stopping suddenly is generally safe, but discuss any changes with your healthcare provider.
Semaglutide enhances insulin's blood sugar-lowering effect. Insulin doses typically need to be reduced 20-50% when starting semaglutide to prevent hypoglycemia (dangerously low blood sugar). Work closely with your doctor.
High risk of hypoglycemia (dangerously low blood sugar) when combined. The sulfonylurea dose usually needs to be lowered. Monitor blood sugar closely.
Semaglutide slows how fast the stomach empties, which may affect how well pills are absorbed. Consider taking birth control at a consistent time relative to meals, or discuss alternative contraception.
May affect warfarin absorption and how the body processes it. More frequent INR monitoring (blood tests that check how well warfarin is thinning your blood) is recommended when starting or changing semaglutide doses.
Take thyroid medication on an empty stomach as usual. Semaglutide shouldn't significantly affect absorption if taken at different times.
Never combine GLP-1 (a gut hormone that tells your brain you're full) medications—they work through the same mechanism and combining would increase side effects without additional benefit.
No direct interaction data exists. BPC-157 is sometimes used for gut healing, which could theoretically help with semaglutide's stomach and gut side effects, but this is speculative.
Limited interaction data. Some users combine them, but this should be done under medical supervision as both can affect how the body handles blood sugar.
Long-term GLP-1 (a gut hormone that tells your brain you're full) use may reduce B12 absorption. Consider B12 supplementation, especially if you've been on semaglutide for over a year.
Can help manage constipation from semaglutide. Start slowly to avoid worsening GI symptoms. Psyllium husk is a good option.
Helpful for ensuring adequate protein intake when appetite is reduced. Aim for at least 60-80g protein daily to preserve muscle mass during weight loss.
May help with GI side effects. Some users find them helpful for digestive comfort during semaglutide therapy.
If your BMI is 30 or higher (or 27+ with weight-related health conditions), semaglutide is currently one of the most effective non-surgical weight loss options available. 7 Clinical trials show average weight loss of 15% of body weight—that's 30+ pounds for someone starting at 200 pounds 1.
Semaglutide works by changing the biological signals that drive hunger and cravings. If you've tried to lose weight through willpower alone and found yourself constantly battling hunger, this medication addresses that underlying biology rather than just telling you to eat less 3713.
Originally developed for diabetes, semaglutide excellently controls blood sugar while also promoting weight loss—addressing two major health concerns simultaneously. 35 It can often allow people to reduce or eliminate other diabetes medications 21.
The SELECT trial proved that semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% in people with obesity and existing heart disease—even without diabetes. It's one of the few weight loss medications proven to improve hard cardiovascular outcomes 2.
Semaglutide has been studied in over 20,000 participants across multiple large clinical trials, making it one of the most thoroughly researched weight loss medications available. 128910 The FDA approved it after rigorous review of safety data. While GI side effects are common (especially early on), serious side effects are rare. 17 The SELECT trial showed it actually reduces cardiovascular events, adding a safety benefit beyond just weight loss 2.
The safety profile is supported by multiple Phase 3 trials including STEP 1-4 (weight loss) and SELECT (cardiovascular outcomes), with follow-up extending to nearly 4 years. 128910 Long-term studies continue, and post-marketing surveillance actively monitors for rare adverse events. The thyroid tumor signal seen in rodents has not been confirmed in humans after years of widespread use 715.
Keeping it good
Store new, unopened pens in the refrigerator at 36-46°F (2-8°C). Do not freeze—freezing destroys the medication. Keep in original carton to protect from light. If needed, unopened pens can be stored at room temperature (up to 86°F/30°C) for up to 28 days before first use.
After first use, pens can be stored in the refrigerator or at room temperature up to 86°F (30°C). Use within 56 days of first injection. Always replace the pen cap after use to protect from light. Never store with needle attached.
Not our opinion — the published record
2021
This landmark trial proved semaglutide's effectiveness for weight loss. Participants lost an average of 14.9% of their body weight over 68 weeks (about 33 pounds), compared to just 2.4% with placebo. Over half lost more than 15% of their body weight—results previously only seen with surgery.
Wilding JPH, Batterham RL, Calanna S, et al.
2023
This massive trial of 17,604 people proved semaglutide reduces heart attacks, strokes, and death from heart and blood vessel causes by 20% in people with obesity and heart disease, even without diabetes. This was the first time a weight loss medication showed direct heart benefits.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.
2025
This comprehensive review traced semaglutide's development from laboratory discovery to clinical breakthrough, documenting its expanding role beyond diabetes into obesity treatment and metabolic liver disease—cementing its status as a transformative therapy.
Weiskirchen R, Lonardo A
2025
Head-to-head comparisons show both medications are highly effective, with tirzepatide producing somewhat greater weight loss in some studies. However, semaglutide has more long-term safety data and the SELECT cardiovascular outcomes trial supporting its use.
Mondoh A, Crotty M, le Roux CW
2025
Semaglutide injected under the skin is started at 0.25 mg once weekly for 4 weeks, then increased to 0.5 mg, then 1 mg, then up to a maximum of 2 mg once weekly, with at least 4 weeks between increases.
Novo Nordisk / U.S. FDA
2024
Semaglutide taken by mouth is started at 3 mg once daily for 30 days (a starting dose that does not control blood sugar), then increased to 7 mg once daily, and may be increased to a maximum of 14 mg once daily. It is taken on an empty stomach with up to 4 oz water, 30 minutes before food or other medicines.
Novo Nordisk / U.S. FDA
2024
US label for semaglutide 2.4 mg for long-term weight management and for lowering the risk of heart and blood vessel disease. Carries a boxed warning (the FDA's strongest safety warning) for thyroid C-cell tumors seen in rodents. It must not be used by anyone with a personal or family history of MTC (medullary thyroid carcinoma, a rare thyroid cancer) or MEN 2 (multiple endocrine neoplasia type 2, an inherited condition that raises the risk of certain tumors). Approved for a BMI of 30 or greater, or 27 or greater with at least one weight-related health condition. The dose is stepped up slowly (titration): 0.25 mg weekly for 4 weeks, then raised every 4 weeks to a 2.4 mg ongoing (maintenance) dose, explicitly 'to minimize gastrointestinal adverse reactions' (stomach and gut side effects). Side effects in 2,116 adults: nausea 44%, diarrhea 30%, vomiting 24%, constipation 24%, abdominal pain 20%, hair loss 3%. Gallstones (cholelithiasis) 1.6% and gallbladder inflammation (cholecystitis) 0.6%, versus 0.7% and 0.2% on placebo. Acute pancreatitis (sudden inflammation of the pancreas) was confirmed by independent review in 4 patients (0.2 per 100 patient-years). Semaglutide is 94% homologous to human GLP-1 (matching in structure), changed at position 8 to resist DPP-4 breakdown and attached to a C18 fatty di-acid at lysine 26 through a water-friendly spacer. More than 99% of it binds to albumin (a blood protein), and its elimination half-life (the time for half to clear) is approximately 1 week. It delays gastric emptying (slows how fast the stomach empties), lowers calorie intake, and causes more loss of fat mass than lean mass (muscle and other non-fat tissue). The dose may be given any time of day with or without food. Taking insulin or an insulin secretagogue (a drug that makes the body release more insulin) at the same time may require a dose reduction.
Novo Nordisk / U.S. FDA
2021
In 1,210 adults with overweight or obesity and type 2 diabetes, semaglutide 2.4 mg once weekly reduced body weight by 9.6% at 68 weeks versus 3.4% with placebo, and 68.8% versus 28.5% achieved at least 5% weight loss. Stomach and gut (gastrointestinal) side effects, mostly mild to moderate, occurred in 63.5% of the 2.4 mg group.
Davies M, Færch L, Jeppesen OK, et al.
2021
In 611 adults with overweight or obesity, semaglutide 2.4 mg weekly plus intensive behavioral therapy reduced body weight by 16.0% at 68 weeks versus 5.7% with placebo; 55.8% versus 13.2% lost at least 15% of baseline weight.
Wadden TA, Bailey TS, Billings LK, et al.
If this isn't the right fit
Your questions
Clinical trials showed an average of about 15% of body weight over 68 weeks—that's roughly 35 pounds for someone starting at 230 pounds. But results vary widely: about 30% of people lose more than 20% of their weight, while some lose less. Diet quality, physical activity, and individual biology all play roles 1.
The gradual dose escalation isn't about being cautious—it's essential for tolerability. Starting at the full dose would cause severe nausea and vomiting in most people. The 4-week increases let your GI system adapt gradually, making side effects much more manageable. Patience during this phase pays off 57.
Most people regain significant weight after stopping—studies show about two-thirds of lost weight returns within a year. 11 This isn't a moral failing; it's biology. The medication is treating the underlying metabolic and neurological drivers of obesity, and those return when the medication stops. Most people need long-term treatment 10.
Current data from clinical trials extending to 4+ years shows a consistent safety profile. 27 The SELECT trial followed patients for an average of 40 months and showed cardiovascular benefits, not harms. That said, it's a relatively new medication (approved 2017 for diabetes, 2021 for obesity), 3 and longer-term monitoring continues.
Some muscle loss occurs with any significant weight loss, including with semaglutide—roughly 25-40% of weight lost may be lean mass. 18 To minimize this: prioritize protein (aim for 1g per pound of goal body weight), include resistance training, and ensure adequate total nutrition. Don't skip meals just because you're not hungry.
Alcohol isn't contraindicated, but many users find their tolerance decreases significantly. Alcohol can also worsen nausea and GI side effects, lower blood sugar (especially in diabetics), and provides empty calories that can slow weight loss. Most people naturally drink less 19 because it just doesn't appeal to them as much.
In rodent studies, semaglutide and other GLP-1 (a gut hormone that tells your brain you're full) drugs caused thyroid C-cell tumors. 7 However, rodents have many more GLP-1 receptors in their thyroid than humans. 14 After years of widespread human use (millions of prescriptions), no clear increase in thyroid cancer has been seen. 15 Still, it's contraindicated if you have a personal or family history of medullary thyroid cancer.
They're both semaglutide, just different doses and indications. Ozempic (max 2mg/week) is FDA-approved for type 2 diabetes. Wegovy (max 2.4mg/week) is FDA-approved for chronic weight management. If you don't have diabetes and want it primarily for weight loss, Wegovy is the appropriate product, though both cause weight loss 57.
22 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Semaglutide research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Semaglutide is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.
PeptideGeek